New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT05668884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of four drugs—two chemotherapy drugs (gemcitabine and oxaliplatin), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in 93 people with advanced biliary tract cancer that has spread. The goal is to see if this mix can shrink tumors and improve survival. Participants must be in fairly good health and have measurable tumors. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gemcitabine, Oxaliplatin, Donafenib, and Tislelizumab
- What this could lead to
- If successful, this combination could offer a new treatment option that shrinks tumors and delays cancer progression in people with advanced biliary tract cancer.
- What could go wrong
- This is an early phase 2 trial with only 93 participants, so results may not apply to everyone. The combination of four drugs may cause significant side effects, and it is not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200062, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug combo aims to fight deadly gallbladder cancer
- Immunotherapy drug shows promise in bile duct cancer trial
- Immunotherapy combo shows promise for tough bile duct cancer
- Tumor DNA study aims to unlock secrets of drug resistance
- New cocktail of drugs shows promise for Tough-to-Treat bile duct cancer